Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05811754 · ClinicalTrials.gov registry record
Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions
A clinical trial of Herpes Zoster, sponsored by GlaxoSmithKline.
- Active
- Registry status
- 2,844
- Enrollment target
- 1
- Study location
NCT05811754 is a study of Herpes Zoster that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 2,844 participants, above the 1,996-participant average among 16 other Herpes Zoster trials with a reported enrollment target (42% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05811754, a study of Herpes Zoster, is active but no longer recruiting, sponsored by GlaxoSmithKline.
- ACTIVE NOT RECRUITING
- Registry status
- 2,844 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this post-marketing commitment safety study is to evaluate the real-world safety of HZ/su vaccine during pregnancy in immunodeficient or immunosuppressed adult pregnant women between 18 and 49 years of age in the United States. The primary outcome of interest is major congenital malformations (MCMs).
Conditions Studied
Interventions
- OTHER Data collection
Study Locations (1)
Massachusetts
- GSK Investigational Site - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,844 participants |
| Start Date | 2022-05-09 |
| Est. Completion | 2028-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05811754
The ClinicalTrials.gov registry entry for NCT05811754 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 2,844 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,996-participant average among 16 other Herpes Zoster trials with a reported enrollment target (42% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Herpes Zoster appearing as the primary indexed condition, and to 1 intervention - of which Data collection is the first listed.
NCT05811754 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05811754 about?
NCT05811754 is a clinical study titled "Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions". The purpose of this post-marketing commitment safety study is to evaluate the real-world safety of HZ/su vaccine during pregnancy in immunodeficient or immunosuppressed adult pregnant women between 18 and 49 years of age in the United States. The primary outcome of interest is major congenital malfo...
What is the current status of trial NCT05811754?
This trial is currently active not recruiting. The enrollment target is 2,844 participants. The study started on 2022-05-09. Estimated completion is 2028-03-31.
What conditions does trial NCT05811754 study?
This clinical trial studies the following conditions: Herpes Zoster.
What interventions are being tested in trial NCT05811754?
The interventions under investigation include: Data collection (OTHER).
Who is sponsoring clinical trial NCT05811754?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05811754 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Herpes Zoster
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
RECRUITING · Phase 1
-
Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age
ACTIVE NOT RECRUITING · Phase 1
-
A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults
ACTIVE NOT RECRUITING · Phase 3
-
The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.